Literature DB >> 2779776

Computed tomographic features of esthesioneuroblastoma.

R W Hurst1, S Erickson, W S Cail, S A Newman, P A Levine, J Burke, R W Cantrell.   

Abstract

Esthesioneuroblastomas are uncommon neoplasms of the superior nasal cavity originating from olfactory epithelium. High resolution CT features of this neoplasm have not been well studied. Nine cases of esthesioneuroblastoma were reviewed to evaluate findings on high resolution CT. Homogeneous soft tissue masses with relatively uniform enhancement centered in the superior nasal cavity are characteristic. Bony erosion is frequent and usually accompanied by molding of bone. Staging, determined by extension and critical for treatment decisions, is well evaluated by CT.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2779776     DOI: 10.1007/BF00344354

Source DB:  PubMed          Journal:  Neuroradiology        ISSN: 0028-3940            Impact factor:   2.804


  17 in total

1.  Primary intranasal neuroblastoma; report of 3 cases.

Authors:  L A SCHALL; M LINEBACK
Journal:  Ann Otol Rhinol Laryngol       Date:  1951-03       Impact factor: 1.547

Review 2.  Esthesioneuroblastoma.

Authors:  D Elkon; S I Hightower; M L Lim; R W Cantrell; W C Constable
Journal:  Cancer       Date:  1979-09       Impact factor: 6.860

3.  Esthesioneuroblastoma: the University of Virginia experience 1960-1985.

Authors:  P A Levine; W C McLean; R W Cantrell
Journal:  Laryngoscope       Date:  1986-07       Impact factor: 3.325

4.  Radiographic features of olfactory neuroblastoma.

Authors:  J E Rosengren; B S Jing; S Wallace; J Danziger
Journal:  AJR Am J Roentgenol       Date:  1979-06       Impact factor: 3.959

5.  Esthesioneuroblastoma: diagnosis and management.

Authors:  E T Newbill; M E Johns; R W Cantrell
Journal:  South Med J       Date:  1985-03       Impact factor: 0.954

6.  Olfactory neuroblastoma: an ultrastructural study.

Authors:  J B Taxy; D F Hidvegi
Journal:  Cancer       Date:  1977-01       Impact factor: 6.860

7.  Olfactory esthesioneuroblastoma--variables predictive of tumor control and recurrence.

Authors:  M J Homzie; D Elkon
Journal:  Cancer       Date:  1980-12-01       Impact factor: 6.860

8.  The early detection of antral malignancy in the postmaxillectomy patient.

Authors:  P M Som; J M Shugar; H F Biller
Journal:  Radiology       Date:  1982-05       Impact factor: 11.105

9.  Ethmoid sinus disease: CT evaluation in 400 cases. Part III. Craniofacial resection.

Authors:  P M Som; W Lawson; H F Biller; C F Lanzieri; V P Sachdev; D Rigamonti
Journal:  Radiology       Date:  1986-06       Impact factor: 11.105

10.  Computed tomography in olfactory neuroblastoma: one case of esthesioneuroepithelioma and four cases of esthesioneuroblastoma.

Authors:  C Manelfe; A Bonafé; P Fabre; J J Pessey
Journal:  J Comput Assist Tomogr       Date:  1978-09       Impact factor: 1.826

View more
  5 in total

1.  Esthesioneuroblastoma in a young child.

Authors:  B Gül; S Kulaçoğlu; M Yüksel; H Doğan; A I Okten
Journal:  Neurosurg Rev       Date:  1997       Impact factor: 3.042

2.  Hyperostotic esthesioneuroblastoma: rare variant and fibrous dysplasia mimicker.

Authors:  Manzoor Ahmed; Phillip Daniel Knott
Journal:  Korean J Radiol       Date:  2014-01-08       Impact factor: 3.500

3.  Atypical aesthesioneuroblastoma: CT and MRI findings.

Authors:  P Vanhoenacker; R Hermans; W Sneyers; H Vanderperre; J Clarysse; R Loncke; A L Baert
Journal:  Neuroradiology       Date:  1993       Impact factor: 2.804

4.  Ectopic primary olfactory neuroblastoma of the nasopharynx: A case report and review of the literature.

Authors:  Nicholas J Caldwell; T Shawn Sato
Journal:  Radiol Case Rep       Date:  2019-06-06

5.  Utility of CT texture analysis to differentiate olfactory neuroblastoma from sinonasal squamous cell carcinoma.

Authors:  Masaki Ogawa; Satoshi Osaga; Norio Shiraki; Daisuke Kawakita; Nobuhiro Hanai; Tsuneo Tamaki; Satoshi Tsukahara; Takatsune Kawaguchi; Misugi Urano; Yuta Shibamoto
Journal:  Sci Rep       Date:  2021-02-25       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.